Skip to main content

ME

Stock
Health Care
Diagnostics & Research

Performance overview

ME Price
Price Chart

Forward-looking statistics

Beta
1.44
Risk
99.21%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees719
Market cap$198.1M

Fundamentals

Enterprise value$1.0M
Revenue$208.8M
Revenue per employee
Profit margin-186.98%
Debt to equity96.53

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$17.39
Dividend per share
Revenue per share$8.27
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$556K
Put-call ratio

Macro factor sensitivity

Growth+18.9
Credit-4.6
Liquidity-12.8
Inflation+15.0
Commodities+6.1
Interest Rates-1.4

Valuation

Dividend yield0.00%
PEG Ratio-0.01
Price to sales0.06
P/E Ratio-0.01
Enterprise Value to Revenue0.01
Price to book0.26

Upcoming events

Next earnings dayAugust 9, 2023
Next dividend day
Ex. dividend day

News

Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates

Medpace (MEDP) came out with quarterly earnings of $3.1 per share, beating the Zacks Consensus Estimate of $3 per share. This compares to earnings of $2.75 per share a year ago.

Zacks Investment Research (July 21, 2025)
OGN or MEDP: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research (July 21, 2025)
Is a Beat in the Cards for CME Group This Earnings Season?

CME's second-quarter performance is likely to have benefited from a diverse product portfolio, increased volatility and a strong market position.

Zacks Investment Research (July 21, 2025)
Wall Street Analysts Think Emcor Group (EME) Is a Good Investment: Is It?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research (July 21, 2025)
GameStop Corp. (GME) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to GameStop (GME). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research (July 21, 2025)
Top Wall Street analysts are confident about the potential of these 3 stocks

TipRanks' analyst ranking service spotlights three stocks, including Uber Technologies and Alphabet, favored by Wall Street.

CNBC (July 20, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free